Miyagawa, Ippei
Nakayamada, Shingo
Ueno, Masanobu
Miyazaki, Yusuke
Iwata, Shigeru
Kubo, Satoshi
Sonomoto, Koshiro
Anan, Junpei
Ohkubo, Naoaki
Inoue, Yoshino
Tanaka, Yoshiya http://orcid.org/0000-0002-0807-7139
Article History
Received: 16 January 2022
Accepted: 22 March 2022
First Online: 15 April 2022
Declarations
:
: Ethical approval was obtained from the University of Occupational and Environmental Health, Japan Ethics Committee (approval number #04-23), based on the Helsinki Declaration, informed consent was obtained from all patients of the FIRST registry.
: Not applicable.
: Y. Tanaka has received speaking fees and/or honoraria from Daiichi-Sankyo, Eli Lilly, Novartis, YL Biologics, Bristol-Myers, Eisai, Chugai, Abbvie, Astellas, Pfizer, Sanofi, Asahi-kasei, GSK, Mitsubishi-Tanabe, Gilead, and Janssen; research grants from Abbvie, Mitsubishi-Tanabe, Chugai, Asahi-Kasei, Eisai, Takeda, and Daiichi-Sankyo; and consultant fees from Eli Lilly, Daiichi-Sankyo, Taisho, Ayumi, Sanofi, GSK, and Abbvie.S. Nakayamada received consulting fees, speaking fees, and/or honoraria from Bristol-Myers, Pfizer, GlaxoSmithKline, Sanofi, Astellas, Asahi-kasei, and Boehringer Ingelheim and research grants from Mitsubishi-Tanabe and Novartis.